MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's President and CEO, Kent Hawryluk, will deliver a podium presentation on Monday, April 7, 2025, from 8:00 a.m. to 8:40 a.m. ET. The presentation will be accompanied by one-on-one meetings.

Investors can access the live webcast through the investors section of MBX Biosciences' website at investors.mbxbio.com/news-events/events. A replay will be available approximately two hours after the event and will remain accessible for about 90 days on the company's website.

News Market Reaction

-0.51%

1 alert

-0.51% News Effect

On the day this news was published, MBX declined 0.51%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference.

24th Annual Needham Virtual Healthcare Conference
Date: Monday, April 7, 2025
Format: Podium Presentation and 1x1 meetings
Time: 8:00 a.m. – 8:40 a.m. ET

The live webcast can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.

About MBX Biosciences 
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND filing anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.

Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889

Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

FAQ

When is MBX Biosciences presenting at the Needham Healthcare Conference 2025?

MBX Biosciences will present on Monday, April 7, 2025, from 8:00 a.m. to 8:40 a.m. ET at the 24th Annual Needham Virtual Healthcare Conference.

How can investors watch MBX Biosciences' Needham Conference presentation?

Investors can watch the live webcast through MBX Biosciences' investor relations website at investors.mbxbio.com/news-events/events.

How long will MBX Biosciences' Needham Conference presentation replay be available?

The presentation replay will be available approximately two hours after the event and will be archived for approximately 90 days on the company's website.

What type of therapies is MBX Biosciences (MBX) developing?

MBX Biosciences is developing novel precision peptide therapies focused on treating endocrine and metabolic disorders.